Colleen Silk is the Corporate Vice President, Rare Disease at Novo Nordisk Inc., a role she assumed in July 2025. Colleen is responsible for the US strategy and execution of Novo Nordisk’s rare disease portfolio. She leads the team responsible for delivering transformative patient and customer experiences and addressing unmet needs across the rare disease communities we serve.

Colleen has over two decades of experience across the healthcare industry, including leadership roles in both large pharmaceutical and emerging biotech organizations. Prior to joining NNI, Colleen served as Vice President and General Manager at Insmed, where she led the global program team for core development assets in immunology. In this role, she oversaw global clinical development, regulatory affairs and commercial strategy. Colleen also served as Head of Marketing and Head of US Sales for Insmed, where she built and led commercial teams to successfully launch a first-in-class pulmonary rare disease product.

Colleen began her pharmaceutical career at Janssen Pharmaceuticals (J&J Innovative Medicine), where she oversaw global strategy in virology and launched brands in the diabetes and cardiovascular spaces.  

Colleen holds an MBA from Georgetown University’s McDonough School of Business and a Bachelor of Science in Health Systems from Georgetown University.